Pharma Opportunity Certificate
There has been an unprecedented eruption of global pharmaceutical research and development related to COVID-19. More than 330 clinical studies and 80 vaccine candidates are currently under review. Big pharma and biotech companies are working to find a drug to manage or defeat COVID-19. With the Pharma Opportunity Certificate, you invest in the performance of companies that are actively working on medicines to combat the coronavirus by developing vaccines or treatments.
• Increased growth potential
• Broad diversification
• Professionally and actively managed
• Traded on the SIX Swiss Exchange
• CHF 9.- flat transaction costs